BioInvent International AB announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the anti-TNFR2 antibody BI-1808 will be granted. The patent provides composition-of matter protection for BI-1808 and the use of the antibody for the treatment of cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.6 SEK | -1.57% | +14.11% | +98.31% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.31% | 233M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- BioInvent International Gains Patent for BI-1808 in China